Compounds > iotrex
Page last updated: 2024-11-13

iotrex

Description

iotrex: used as radiation source for brachytherapy; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID22263260
MeSH IDM0380468

Synonyms (5)

Synonym
sodium 3-(i sub 125)iodo-4-hydroxybenzene sulfonate
nsc-722133
iotrex
nsc722133
sodium;4-hydroxy-3-iodobenzenesulfonic acid

Research Excerpts

Overview

Iotrex is an aqueous radiotherapy solution containing sodium 3-(125I)iodo-4-hydroxybenzenesulfonate (125I-HBS) It is used as the radiation source for the brachytherapy of resected of brain tumor cavity margins.

ExcerptReferenceRelevance
"Iotrex is an aqueous radiotherapy solution containing sodium 3-(125I)iodo-4-hydroxybenzenesulfonate (125I-HBS), which is used as the radiation source for the brachytherapy of resected of brain tumor cavity margins with the GliaSite catheter. "( Biodistribution and dosimetry of an aqueous solution containing sodium 3-(125I)iodo-4-hydroxybenzenesulfonate (Iotrex) for brachytherapy of resected malignant brain tumors.
Frank, RK; McMillan, K; Simón, J; Strickland, AD; Stubbs, JB; Williams, JA, 2000)		1.96

Toxicity

ExcerptReferenceRelevance
" The careful manipulation of such solutions is important to maintain a safe environment for the patients and the involved medical staff."( Radiation safety issues with high activities of liquid I-125: techniques and experience.
Amadeo, H; deGuzman, AF; Hinson, WH; Kearns, WT; Shaw, E; Stieber, V; Tatter, S; Yates, C, 2003)		0.32
" There were no serious adverse device-related events during brachytherapy."( An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial.
Brem, S; Carson, K; Crocker, IR; Fisher, JD; Grossman, SA; Karvelis, KC; Kleinberg, L; Olson, JJ; Pearlman, JL; Rosenblum, ML; Shaw, EG; Tatter, SB; Weingart, J, 2003)		0.32
" Precautions during treatment included safe handling of body fluids."( Balloon brachytherapy for brain tumor-radiation safety experiences at the University of Medicine and Dentistry of New Jersey.
Lanka, VK, 2006)		0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.15 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms, Brain
[description not available]		03.470
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		03.470
Glial Cell Tumors
[description not available]		02.0110
Local Neoplasm Recurrence
[description not available]		02.4220
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.0110
Anaplastic Astrocytoma
[description not available]		02.0210
Astrocytoma, Grade IV
[description not available]		02.4220
Injuries, Radiation
[description not available]		02.0210
Astrocytoma
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)		02.0210
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.4220
chemdatabank.com